Literature DB >> 22583117

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

Jaehyup Kim1, Ryan A Denu, Bridget A Dollar, Leah E Escalante, Justin P Kuether, Natalie S Callander, Fotis Asimakopoulos, Peiman Hematti.   

Abstract

Multiple myeloma (MM) is characterized by almost exclusive tropism of malignant cells for the bone marrow (BM) milieu. The survival and proliferation of malignant plasma cells have been shown to rely on interactions with nonmalignant stromal cells, in particular mesenchymal stromal cells (MSCs), in the BM microenvironment. However, the BM microenvironment is composed of a diverse array of cell types. This study examined the role of macrophages, an abundant component of BM stroma, as a potential niche component that supports malignant plasma cells. We investigated the proliferation of MM tumour cell lines when cultured alone or together with MSCs, macrophages, or a combination of MSCs and macrophages, using the carboxyfluorescein succinimidyl ester assay. Consistently, we observed increased proliferation of MM cell lines in the presence of either MSCs or macrophages compared to cell line-only control. Furthermore, the combined co-culture of MSCs plus macrophages induced the greatest degree of proliferation of myeloma cells. In addition to increased proliferation, MSCs and macrophages decreased the rate of apoptosis of myeloma cells. Our in vitro studies provide evidence that highlights the role of macrophages as a key component of the BM microenvironment facilitating the growth of malignant plasma cells in MM.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583117      PMCID: PMC3395762          DOI: 10.1111/j.1365-2141.2012.09154.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  76 in total

Review 1.  Mesenchymal stem cells: paradoxes of passaging.

Authors:  Elisabeth H Javazon; Kirstin J Beggs; Alan W Flake
Journal:  Exp Hematol       Date:  2004-05       Impact factor: 3.084

2.  From IFN to TNF: a journey into realms of lore.

Authors:  Jan Vilcek
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

3.  Mutations in the Fas antigen in patients with multiple myeloma.

Authors:  T H Landowski; N Qu; I Buyuksal; J S Painter; W S Dalton
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

4.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

5.  Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts.

Authors:  A Karadag; B O Oyajobi; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

Review 6.  Lenalidomide: a novel anticancer drug with multiple modalities.

Authors:  Christine Galustian; Angus Dalgleish
Journal:  Expert Opin Pharmacother       Date:  2009-01       Impact factor: 3.889

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

8.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

Review 9.  Emerging therapies for multiple myeloma.

Authors:  Klaus Podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

Review 10.  Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Authors:  Constantine S Mitsiades; Faith E Davies; Jacob P Laubach; Douglas Joshua; Jesus San Miguel; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

View more
  53 in total

1.  Comparison of breast and abdominal adipose tissue mesenchymal stromal/stem cells in support of proliferation of breast cancer cells.

Authors:  Jaehyup Kim; Leah E Escalante; Bridget A Dollar; Summer E Hanson; Peiman Hematti
Journal:  Cancer Invest       Date:  2013-09-10       Impact factor: 2.176

2.  MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Authors:  Chorom Pak; Natalie S Callander; Edmond W K Young; Benjamin Titz; KyungMann Kim; Sandeep Saha; Kenny Chng; Fotis Asimakopoulos; David J Beebe; Shigeki Miyamoto
Journal:  Integr Biol (Camb)       Date:  2015-05-22       Impact factor: 2.192

Review 3.  Macrophages in multiple myeloma: key roles and therapeutic strategies.

Authors:  Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

Review 4.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 5.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.

Authors:  Mailee Huynh; Chorom Pak; Stephanie Markovina; Natalie S Callander; Kenneth S Chng; Shelly M Wuerzberger-Davis; Debayan D Bakshi; John A Kink; Peiman Hematti; Chelsea Hope; Fotis Asimakopoulos; Lixin Rui; Shigeki Miyamoto
Journal:  J Biol Chem       Date:  2017-12-26       Impact factor: 5.157

Review 7.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

8.  MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.

Authors:  Ellen Hebron; Chelsea Hope; Jaehyup Kim; Jeffrey L Jensen; Claire Flanagan; Neehar Bhatia; Ioanna Maroulakou; Constantine Mitsiades; Shigeki Miyamoto; Natalie Callander; Peiman Hematti; Fotis Asimakopoulos
Journal:  Br J Haematol       Date:  2012-12-18       Impact factor: 6.998

9.  Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model.

Authors:  Jaehyup Kim; Esmail D Zanjani; Christine M Jeanblanc; A Daisy Goodrich; Peiman Hematti
Journal:  Exp Hematol       Date:  2013-04-20       Impact factor: 3.084

10.  To b(ortezomib) or not to be: the stroma's the thing.

Authors:  Maxwell M Krem; Jun Yan
Journal:  J Pathol       Date:  2016-09-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.